Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0195
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity- 9:00AM-11:00AM
-
Abstract Number: 0408
Epidemiology and Treatment of Behçet’s Disease Insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0377
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0265
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0292
Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0365
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0012
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease- 9:00AM-11:00AM
-
Abstract Number: 0410
Exploring Gene Expression Profile of Primary Central Nervous System Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0300
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0282
Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0271
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0246
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0263
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations